{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Trimetrexate",
  "nciThesaurus": {
    "casRegistry": "52128-35-5",
    "chebiId": "",
    "chemicalFormula": "C19H23N5O3",
    "definition": "A methotrexate derivative with potential antineoplastic activity.  Trimetrexate inhibits the enzyme dihydrofolate reductase, thereby preventing the synthesis of purine nucleotides and thymidylate, with subsequent inhibition of DNA and RNA synthesis.  Trimetrexate also exhibits antiviral activity.",
    "fdaUniiCode": "UPN4ITI8T4",
    "identifier": "C1314",
    "preferredName": "Trimetrexate",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C2153",
      "C511"
    ],
    "synonyms": [
      "2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-",
      "5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine",
      "CI-898",
      "TMQ",
      "TRIMETREXATE",
      "Trimetrexate",
      "Trimexate"
    ]
  }
}